Abstract | BACKGROUND: METHODS: Phase II trials were identified using a MEDLINE search, and the Cochrane Central Register of Controlled Trials from 1960 to July 2010. Patients were divided into 2 groups: Patients with initially resectable tumors (group A), and patients with borderline/unresectable tumors (group B). Primary outcome measures were rate of resection and survival. Pooled proportions and 95% confidence intervals (CIs) were calculated using random-effects or fixed-effects models based on the heterogeneity of included studies. RESULTS: A total of 14 phase II clinical trials including 536 patients were analyzed. After treatment, resectability was 65.8% (95% CI, 55.4-75.6%) compared with 31.6% in group B (95% CI, 14.0-52.5%). A partial response was observed in patients with borderline/unresectable tumors; 31.8 (95% CI, 24.2-39.8%) in group B and 9.5% (95% CI, 2.9-19.4%) in group A (P = .003). Progressive disease was seen in 17.0% (95% CI, 11.9-22.7) of patients in group A versus 21.8% (95% CI, 10.1-36.5%) in group B (P = .006). Median survival in resected patients was 23 months for group A and 22 months for group B. CONCLUSION:
|
Authors | M Mura Assifi, Xuyang Lu, Guido Eibl, Howard A Reber, Gang Li, O Joe Hines |
Journal | Surgery
(Surgery)
Vol. 150
Issue 3
Pg. 466-73
(Sep 2011)
ISSN: 1532-7361 [Electronic] United States |
PMID | 21878232
(Publication Type: Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural, Review)
|
Copyright | Copyright © 2011 Mosby, Inc. All rights reserved. |
Topics |
- Adenocarcinoma
(mortality, pathology, therapy)
- Adult
- Aged
- Clinical Trials, Phase II as Topic
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Neoadjuvant Therapy
(methods)
- Pancreatectomy
(methods, mortality)
- Pancreatic Neoplasms
(mortality, pathology, therapy)
- Prognosis
- Survival Analysis
|